跳至主要内容
临床试验/NCT02441153
NCT02441153已完成不适用

T4RC North: Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy; Does a Longer Wait Improve Outcomes?

Health Sciences North Research Institute0 个研究点目标入组 50 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
主要终点
Disease-free survival

研究概览

简要总结

This pilot study will take place at Health Sciences North (HSN) in Sudbury. Patients will be identified and screened for inclusion into the study once referred to a general or colorectal surgeon for resection of their rectal cancer. This may occur before or after preoperative chemoradiotherapy (CRT) but randomization will take place after CRT.

详细描述

The main question of this study is whether or not delaying surgery after preoperative CRT increases disease-free survival. The standard 6-7 week waiting period will be compared to 10-11 weeks, which was the time-frame identified in the Dutch Surgical Colorectal Audit as increasing the likelihood of pCR the most. This trial will also be able to determine if an increased waiting interval increases the rate of sphincter-preservation, local recurrence, and pCR. While similar to the GRECCAR-6 trial, our primary outcome is disease-free survival (a more clinically relevant outcome) and is the first North American clinical trial of this nature.

To maximize the utility of this trial, immunohistochemical staining will be performed on pre-CRT tumor samples to prospectively validate the scoring system proposed by Hur et al. [28] The question being whether or not expression of these biomarkers can predict which patients will experience pCR and disease-free survival.

The pilot will be constructed as a prospective, open-label clinical trial, with patients being randomized to undergo surgery at 6-7 weeks or 10-11 weeks after completion of preoperative CRT. The intention is that once preliminary data is available, other centres in Ontario will be recruited. This will not only help answer our research question, but also create a large, prospective database of rectal cancer patients. The Primary outcome (disease-free survival) will be assessed at 3 years.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (>18 years)
  • T3/4N0M0 or TxN+M0 rectal cancer below or at the peritoneal reflection, confirmed on clinical exam, histology, pelvic MRI, and CT chest/abdo
  • Patients who have completed a CRT protocol for the above tumor at HSN
  • Informed consent given
  • Surgical resection with TME planned

排除标准

  • Metastatic disease
  • Failure to complete preoperative CRT
  • Unable to give free and informed consent
  • Unable to comply with the requirements of the study
  • Previous malignancy other than nonmelanoma skin cancer, papillary or follicular thyroid cancer
  • Inflammatory bowel disease
  • Hereditary colorectal cancer

结局指标

主要结局

Disease-free survival

时间窗: 3 years post surgery

The absence of any local recurrence or metastatic disease discovered on physical exam, endoscopy, or imaging

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验